CTLs play a critical role in �ghting chronic virus infection and cancers. Despite the tremendous efforts spent so far, generating potent and highly effective CTLs remain a major roadblock for disease control (prevention and therapies). Activation of CTLs requires different stimuli and is in�u-enced by different disease conditions. In this special issue, several papers investigated functions of cytokines, such as IL-15 and IL-6, in activation of CTLs. Several papers are focusing on the therapeutic effects of CTLs in different cancers using novel approaches targeting tumor-speci�c CTLs. In addition, potential markers and mechanisms for rapid progression of AIDS are suggested using SIV model.
In the �rst paper entitled "IL-6 production by dendritic cells is dispensable for + memory T-cell generation," Daudelin et al. describe a new observation that IL-6 is not required in APC vaccination.
In the second paper entitled "What is recent in pancreatic cancer immunotherapy?" Niccolai et al. summarize the current immunotherapy of pancreatic cancer targeting cancerassociated antigens.
In the third paper entitled "MUC1-speci�c cytotoxic T lymphocytes in cancer therapy: induction and challenge," Roulois et al. review current knowledge regarding MUC1 as a potential target tumor therapeutic vaccines.
In the fourth paper entitled "Characterization of We thank all of the authors for their great contributions to this special issue and appreciate their patience in processing their manuscripts. We also want to thank all of the reviewers who went through the manuscripts multiple times, providing insightful suggestions. We really hope this special issue will continue to thrive as a timely communication platform for basic and translational research on CTLs.
